Kenvue Inc. (KVUE) Stock

Consumer StaplesHousehold & Personal Products Website

KVUE has an Alpha Score of 56 out of 100 (moderate), computed on Oct 30, 2026 from 3 of 4 sub-scores. 9 members of Congress disclosed 26 trades in KVUE since 2023: 11 purchases and 15 sales, most recently Kevin Hern (sale, Aug 5, 2026). 9 of the hedge funds AlphaScala tracks reported KVUE in 13F filings for the quarter ended Jun 30, 2026; the largest reported position is Millennium Management's at $705.90M. Its trailing P/E ratio is 22.4 and its net margin 10.8% (key statistics as of Nov 4, 2026).

$19.31
Last price on Oct 30, 2026
Source: Finnhub
Alpha Score
56
Moderate

What is KVUE's Alpha Score?

How it works →

Alpha Score of 56 reflects moderate overall profile with strong momentum, weak value, moderate quality. Based on 3 of 4 signals – score is capped at 90 until remaining data ingests.

Momentum
84
Strong
Value
47
Weak
Quality
52
Weak

Computed from 3 of 4 sub-scores; a sub-score is left out when its inputs are missing, and the composite is capped accordingly.

Computed Oct 30, 2026

A rules-based research rating, not a recommendation to buy or sell.

Which members of Congress traded Kenvue Inc. (KVUE)?

Members
9
Disclosed trades
26
Purchases
11
Sales
15

Most recent: Kevin Hern (sale, Aug 5, 2026); records start Aug 2, 2023.

PoliticianTrade dateTypeAmount
Kevin Hern
R-OK · House
2026-08-05sale$1k – $15k
Gil Cisneros
D-CA · House
2026-07-17partial sale$1k – $15k
Gil Cisneros
D-CA · House
2026-06-16purchase$1k – $15k
Alan Armstrong
R-OK · Senate
2026-03-27purchase$1k – $15k
Kevin Hern
R-OK · House
2026-03-17sale$15k – $50k
Gil Cisneros
D-CA · House
2026-03-13sale$1k – $15k
Gil Cisneros
D-CA · House
2026-02-10purchase$1k – $15k
Gil Cisneros
D-CA · House
2026-01-09sale$1k – $15k

From STOCK Act periodic transaction reports. House filings as of Nov 2, 2026. Senate records here end Oct 21, 2026; later Senate trades are not included.

Every member of Congress who traded KVUE, with filing lags →

Which hedge funds own KVUE?

From 13F filings
FundShares HeldPosition ValueChange vs prior Q
Millennium Management
Israel Englander
36.94M$705.90M+16%
Citadel
Ken Griffin
11.96M$228.57M+11%
Renaissance Technologies
Jim Simons (founder)
9.02M$172.46M+118%
D.E. Shaw
David Shaw
7.62M$145.55M-71%
Soros Fund Management
George Soros (founder)
2.75M$52.49M-13%
Marshall Wace2.33M$44.49M-84%
Point72
Steve Cohen
808K$15.44M+75%
Bridgewater Associates
Ray Dalio
311K$5.95M+149%
Maverick Capital
Lee Ainslie
174K$3.32M+89%

13F holdings as of Jun 30, 2026

Explore all tracked funds →

What are KVUE's key statistics?

P/E Ratio
22.37
EPS (TTM)
0.86
Beta
-0.79
Net Margin
10.76%
ROE
15.58%
Debt / Equity
0.79
52W High
$20.13
52W Low
$14.02

Key statistics as of Nov 4, 2026

How does KVUE's valuation compare with the Consumer Staples sector?

MetricKVUEConsumer Staples medianCompanies in median
P/E ratio22.419.860
Net margin10.76%6.34%64
Return on equity15.58%14.14%64

Medians over the Consumer Staples stocks whose key statistics were refreshed in the last 35 days (newest Nov 4, 2026). P/E excludes loss-making companies.

KVUE price chart

Powered by TradingView

What does Kenvue Inc. do?

Kenvue Inc. is the world's largest pure-play consumer health company, specializing in science-backed products for everyday care needs. It operates through three key segments: Self Care, offering cough, cold, allergy, pain, digestive health, smoking cessation, and eye care under brands like Tylenol, Motrin, Benadryl, Nicorette, and Zyrtec; Skin Health and Beauty, providing face, body, hair, sun, and other care items via Neutrogena, Aveeno, Rogaine, and OGX; and Essential Health, delivering oral, baby, women's health, wound care, and related products through Listerine, Johnson's, Band-Aid, and Stayfree. Kenvue serves consumers in the United States, Europe, the Middle East, Africa, Asia-Pacific, and Latin America, focusing on trusted, iconic brands that support daily rituals and critical moments with innovation rooted in clinical research and consumer insights. Incorporated in 2022 and headquartered in Summit, New Jersey, Kenvue emphasizes integrity, quality, and solutions endorsed by healthcare professionals across diverse categories like pain relief, skin care, and oral health.

CEO
Mr. Kirk L. Perry
Employees
21,780
Market Cap
$37.09B
Ask about KVUEAI research agent